Wednesday, 1 July 2015

Tonix Pharmaceuticals Holding Corp. - Product Pipeline Review - 2015

Tonix Pharmaceuticals Holding Corp. - Product Pipeline Review - 2015 is a new market research publication announced by Reportstack. This report provides an overview of the Tonix Pharmaceuticals Holding Corp.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Tonix Pharmaceuticals Holding Corp.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by team experts. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Complete report available @ Tonix Pharmaceuticals Holding Corp. - Product Pipeline Review - 2015.

Scope

- The report provides brief overview of Tonix Pharmaceuticals Holding Corp. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Tonix Pharmaceuticals Holding Corp.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Tonix Pharmaceuticals Holding Corp.’s pipeline products

Reasons to buy

- Evaluate Tonix Pharmaceuticals Holding Corp.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Tonix Pharmaceuticals Holding Corp. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Tonix Pharmaceuticals Holding Corp.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Tonix Pharmaceuticals Holding Corp. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Tonix Pharmaceuticals Holding Corp.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Tonix Pharmaceuticals Holding Corp. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

RedHill Biopharma Ltd. - Product Pipeline Review - 2015

RedHill Biopharma Ltd. - Product Pipeline Review - 2015 is a new market research publication announced by Reportstack. This report provides an overview of the RedHill Biopharma Ltd.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of RedHill Biopharma Ltd.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

To view the table of contents and know more details, please visit RedHill Biopharma Ltd. - Product Pipeline Review - 2015.

Scope

- The report provides brief overview of RedHill Biopharma Ltd. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of RedHill Biopharma Ltd.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the RedHill Biopharma Ltd.’s pipeline products

Reasons to buy

- Evaluate RedHill Biopharma Ltd.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of RedHill Biopharma Ltd. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the RedHill Biopharma Ltd.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of RedHill Biopharma Ltd. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of RedHill Biopharma Ltd.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of RedHill Biopharma Ltd. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

ATLAB Pharma SAS - Product Pipeline Review - 2015

ATLAB Pharma SAS - Product Pipeline Review - 2015 is a new market research publication announced by Reportstack. This report provides an overview of the ATLAB Pharma SAS’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of ATLAB Pharma SAS’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by team experts. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

To access full report with TOC, please visit ATLAB Pharma SAS - Product Pipeline Review - 2015.

Scope

- The report provides brief overview of ATLAB Pharma SAS including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of ATLAB Pharma SAS’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the ATLAB Pharma SAS’s pipeline products

Reasons to buy

- Evaluate ATLAB Pharma SAS’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of ATLAB Pharma SAS in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the ATLAB Pharma SAS’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of ATLAB Pharma SAS and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of ATLAB Pharma SAS
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of ATLAB Pharma SAS and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Progenics Pharmaceuticals, Inc. - Product Pipeline Review - 2015

Progenics Pharmaceuticals, Inc. - Product Pipeline Review - 2015 is a new market research publication announced by Reportstack. This report provides an overview of the Progenics Pharmaceuticals, Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Progenics Pharmaceuticals, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by team experts. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Complete report available @ Progenics Pharmaceuticals, Inc. - Product Pipeline Review - 2015.

Scope

- The report provides brief overview of Progenics Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Progenics Pharmaceuticals, Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Progenics Pharmaceuticals, Inc.’s pipeline products

Reasons to buy

- Evaluate Progenics Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Progenics Pharmaceuticals, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Progenics Pharmaceuticals, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Progenics Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Progenics Pharmaceuticals, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Progenics Pharmaceuticals, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Effimune SAS - Product Pipeline Review - 2015

Effimune SAS - Product Pipeline Review - 2015 is a new market research publication announced by Reportstack. This report provides an overview of the Effimune SAS’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Effimune SAS’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

To view the table of contents and know more details, please visit Effimune SAS - Product Pipeline Review - 2015.

Scope

- The report provides brief overview of Effimune SAS including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Effimune SAS’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Effimune SAS’s pipeline products

Reasons to buy

- Evaluate Effimune SAS’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Effimune SAS in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Effimune SAS’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Effimune SAS and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Effimune SAS
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Effimune SAS and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

CYATHUS EXQUIRERE PharmaforschungsGmbH - Product Pipeline Review - 2015

CYATHUS EXQUIRERE PharmaforschungsGmbH - Product Pipeline Review - 2015 is a new market research publication announced by Reportstack. This report provides an overview of the CYATHUS EXQUIRERE PharmaforschungsGmbH’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of CYATHUS EXQUIRERE PharmaforschungsGmbH’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Complete report available @ CYATHUS EXQUIRERE PharmaforschungsGmbH - Product Pipeline Review - 2015.

Scope

- The report provides brief overview of CYATHUS EXQUIRERE PharmaforschungsGmbH including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of CYATHUS EXQUIRERE PharmaforschungsGmbH’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the CYATHUS EXQUIRERE PharmaforschungsGmbH’s pipeline products

Reasons to buy

- Evaluate CYATHUS EXQUIRERE PharmaforschungsGmbH’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of CYATHUS EXQUIRERE PharmaforschungsGmbH in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the CYATHUS EXQUIRERE PharmaforschungsGmbH’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of CYATHUS EXQUIRERE PharmaforschungsGmbH and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of CYATHUS EXQUIRERE PharmaforschungsGmbH
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of CYATHUS EXQUIRERE PharmaforschungsGmbH and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Merz Pharmaceuticals GmbH - Product Pipeline Review - 2015

Merz Pharmaceuticals GmbH - Product Pipeline Review - 2015 is a new market research publication announced by Reportstack. This report provides an overview of the Merz Pharmaceuticals GmbH’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Merz Pharmaceuticals GmbH’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by team experts. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

To access full report with TOC, please visit Merz Pharmaceuticals GmbH - Product Pipeline Review - 2015.
Scope

- The report provides brief overview of Merz Pharmaceuticals GmbH including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Merz Pharmaceuticals GmbH’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Merz Pharmaceuticals GmbH’s pipeline products

Reasons to buy

- Evaluate Merz Pharmaceuticals GmbH’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Merz Pharmaceuticals GmbH in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Merz Pharmaceuticals GmbH’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Merz Pharmaceuticals GmbH and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Merz Pharmaceuticals GmbH
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Merz Pharmaceuticals GmbH and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###